Compare Baxter International Inc (BAX) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs FMC Corp — how do they compare? Baxter International Inc trades at $27.13 (market cap $14.27B), while FMC Corp trades at $10.2 (market cap $1.30B). The key difference: Baxter International Inc is far larger — about 11× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| BAX | FMC | |
|---|---|---|
Market Cap | $14.27B | $1.30B |
Sector | Health | Basic Materials |
52-Week High | $28.35 | $40.69 |
52-Week Low | $15.80 | $10.01 |
Enterprise Value | $21.79B | $5.11B |
Dividend Yield | 0.14% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.09, down 2.48% today but showing strong technical momentum with bullish moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations by 53%, and raised full-year guidance. Despite negative net margins and elevated P/E ratio of 87.85, improving operational performance and positive cash flow projections for 2026 suggest potential turnaround.
The stock presents a mixed outlook with strong technical momentum and recent operational improvements offset by valuation concerns and profitability challenges. Key opportunities include continued execution on raised guidance and debt reduction efforts, while risks center on margin pressure and high debt levels. Analyst consensus leans neutral with 55.55% hold ratings and $25.43 price target below current levels.
FMC stock trades at $10.17, down 2.82% today, amid bearish technical signals and weak fundamentals. Recent Q2 2026 earnings beat estimates but revenue missed, with full-year guidance lowered. The company faces significant profitability challenges, with a net income margin of -84.83% and negative ROE/ROA. Positive developments include a $400 million minority investment from Tessenderlo Group and ongoing debt reduction efforts.
The outlook remains cautious due to persistent earnings pressure and high debt levels, though asset sales and external funding provide liquidity support. Analyst consensus is mixed with a $11.60 price target, suggesting modest upside potential if operational improvements materialize. Key risks include volatile cash flows, competitive pressures, and macroeconomic headwinds affecting agricultural demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
